BioSpace News Archive

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2022 and provided program updates.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that the American Gastroenterological Association recently published a best practice advice article stating that the TissueCypher® Barrett’s Esophagus test may be beneficial for risk-stratification of patients with non-dysplastic Barrett’s esophagus.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced that the accelerator for the MEVION S250i Proton Therapy System® was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China.

IMV Inc. today announced that it will hold a conference call and webcast on Thursday, August 11, 2022, at 8:00 a.m. ET to discuss the company’s 2022 second quarter financial.

The epilepsy monitoring devices market has been estimated to grow at a significant speed in the forthcoming years.

Omega Therapeutics, Inc. announced financial results for the second quarter ended June 30, 2022, and highlighted recent Company progress.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, reported financial results for the second quarter ended June 30, 2022, and provided a business update.

Zoetis Inc. reported its financial results for the second quarter of 2022 and updated its guidance for full year 2022 to reflect its positive outlook for the remainder of the year, as well as the negative impact of recent changes to foreign exchange rates.

Virios Therapeutics, Inc. announced today that its second quarter 2022 financial results will be reported on Thursday, August 11, 2022 before the open of the financial markets.